Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the treatment landscape for patients with cancer. Clinical activity of anti-PD-(L)1 antibodies has resulted in increased median overall survival and durable responses in patients across selected tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Sujatha, Ghosh, Srimoyee, Sharma, Geeta, Wang, Zebin, Kehry, Marilyn R., Marino, Margaret H., Neben, Tamlyn Y., Lu, Sharon, Luo, Shouqi, Roberts, Simon, Ramaswamy, Sridhar, Danaee, Hadi, Jenkins, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317941/
https://www.ncbi.nlm.nih.gov/pubmed/34313545
http://dx.doi.org/10.1080/19420862.2021.1954136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317941/
https://www.ncbi.nlm.nih.gov/pubmed/34313545
http://dx.doi.org/10.1080/19420862.2021.1954136

Ejemplares similares